Effect of Bivalirudin on Primary Percutaneous Coronary Intervention in Patients With Acute ST-elevation Myocardial Infraction
10.3969/j.issn.1000-3614.2015.08.005
- VernacularTitle:比伐芦定在急性ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗术中应用的疗效观察
- Author:
Jiawei WU
;
Likun MA
;
Zhe YANG
;
Hai FAN
- Publication Type:Journal Article
- Keywords:
Bivalirudin;
Heparin;
ST-elevation myocardial infarction;
Percutaneous coronary intervention;
Glycoprotein IIb/IIIa inhibitor
- From:
Chinese Circulation Journal
2015;(8):737-740
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the efifcacy and safety of bivalirudin on primary percutaneous coronary intervention (PCI) in patients with acute ST-elevation myocardial infarction (STEMI).
Methods: A total of 159 patients with acute STEMI treated by emergent PCI in our hospital from 2011-09 to 2014-01 were retrospectively studied. The patients were divided into 2 groups according to procedural bivalirudin application as Bivalirudin group and Heparin group, and the application of GPI (glycoprotein IIb/IIIa inhibitor) was decided by the operator. The baseline condition, coronary artery imaging condition, peri-operative and 30-day post-operative bleeding, the occurrence rate of MACE were compared between 2 groups.
Results: There were 153 patients completed the follow-up study including 72 in Bivalirudin group and 81 in Heparin group. The peri-operative bleeding rates in Bivalirudin group and Heparin group were 6.5% vs 11.0%, the in-stent thrombosis rates were 0% vs 1.2%, 30-day post-operative bleeding rates were 9.7% vs 13.5% and the occurrence of MACE were 1.4% vs 7.4% allP>0.05.
Conclusion: THE application of bivalirudin in emergent PCI is safe and effective in patients with acute STEMI, it has certain trend to reduce bleeding in relevant patients.
